Qingran Yan

机构：China Pharmaceutical University, Renji Hospital, Zhejiang Yongning Pharma (China), Marmara University · ORCID：0000-0002-2781-5280

发表论文 61 篇 · 总被引 748 次 · h-index 15

代表论文

Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis (2023 · Arthritis & Rheumatology · 被引 28)
Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus (2024 · Autoimmunity Reviews · 被引 25)
Quantitative infrapatellar fat pad signal intensity alteration as an imaging biomarker of knee osteoarthritis progression (2023 · RMD Open · 被引 19)
Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome (2022 · Biomedicine & Pharmacotherapy · 被引 19)
Longitudinal association of infrapatellar fat pad signal intensity alteration with biochemical biomarkers in knee osteoarthritis (2022 · Lara D. Veeken · 被引 14)
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database (2025 · Annals of the Rheumatic Diseases · 被引 13)